191 related articles for article (PubMed ID: 15149155)
1. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Violini S; D'Ascenzo S; Bagnoli M ; Millimaggi D; Miotti S; Canevari S; Pavan A; Dolo V
J Exp Clin Cancer Res; 2004 Mar; 23(1):83-91. PubMed ID: 15149155
[TBL] [Abstract][Full Text] [Related]
2. Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells.
Prinetti A; Millimaggi D; D'Ascenzo S; Clarkson M; Bettiga A; Chigorno V; Sonnino S; Pavan A; Dolo V
Biochem J; 2006 Apr; 395(2):311-8. PubMed ID: 16356169
[TBL] [Abstract][Full Text] [Related]
3. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
[TBL] [Abstract][Full Text] [Related]
4. Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma.
Ferguson RE; Jackson SM; Stanley AJ; Joyce AD; Harnden P; Morrison EE; Patel PM; Phillips RM; Selby PJ; Banks RE
Int J Cancer; 2005 May; 115(1):155-63. PubMed ID: 15645438
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sultana H; Iba T; Akeshima R; Kamazawa S; Kanamori Y; Terakawa N
Jpn J Cancer Res; 2002 Jun; 93(6):723-8. PubMed ID: 12079522
[TBL] [Abstract][Full Text] [Related]
6. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
Sackett DL; Giannakakou P; Poruchynsky M; Fojo A
Cancer Chemother Pharmacol; 1997; 40(3):228-32. PubMed ID: 9219506
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
Duan Z; Lamendola DE; Penson RT; Kronish KM; Seiden MV
Cytokine; 2002 Mar; 17(5):234-42. PubMed ID: 12027404
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
[TBL] [Abstract][Full Text] [Related]
9. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
[TBL] [Abstract][Full Text] [Related]
10. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
11. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK
Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014
[TBL] [Abstract][Full Text] [Related]
12. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Ho EA; Soo PL; Allen C; Piquette-Miller M
J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of tyrosinated alpha-, beta(III)-, and beta(IV)-tubulin isotypes in paclitaxel-resistant MCF-7 breast cancer cells.
Banerjee A
Biochem Biophys Res Commun; 2002 Apr; 293(1):598-601. PubMed ID: 12054644
[TBL] [Abstract][Full Text] [Related]
14. Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells.
Balachandran R; Welsh MJ; Day BW
Oncogene; 2003 Dec; 22(55):8924-30. PubMed ID: 14654788
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
[TBL] [Abstract][Full Text] [Related]
16. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
Dumontet C; Duran GE; Steger KA; Beketic-Oreskovic L; Sikic BI
Cancer Res; 1996 Mar; 56(5):1091-7. PubMed ID: 8640766
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Wang C; Guo LB; Ma JY; Li YM; Liu HM
Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547
[TBL] [Abstract][Full Text] [Related]
18. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
Giannakakou P; Poy G; Zhan Z; Knutsen T; Blagosklonny MV; Fojo T
Oncogene; 2000 Jun; 19(27):3078-85. PubMed ID: 10871860
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole.
Chu SW; Badar S; Morris DL; Pourgholami MH
Anticancer Res; 2009 Oct; 29(10):3791-6. PubMed ID: 19846910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
